IMNM · Immunome Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14.02M | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $177.29M | $129.54M | $23.09M | $23.27M | $14.11M | $7.49M |
| SG&A | $43.77M | $32.95M | $19.66M | $13.63M | $11.09M | $4.78M |
| Total Operating Expenses | $231.05M | $314.84M | $123.55M | $36.90M | $25.20M | $12.26M |
| D&A | $2.47M | $1.57M | $457.0K | $422.0K | $755.0K | $755.0K |
| Operating Income | ($224.11M) | ($305.80M) | ($109.53M) | ($36.90M) | ($25.20M) | ($12.26M) |
| Interest Expense | - | - | - | - | - | $21.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($212.39M) | ($292.96M) | ($106.81M) | ($36.90M) | ($24.71M) | ($17.84M) |
| EPS - Basic | ($2.43) | ($5.00) | ($5.38) | ($3.09) | ($5.26) | - |
| EPS - Diluted | ($2.43) | ($5.00) | ($5.38) | ($3.09) | ($5.26) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $653.48M | $143.35M | $98.68M | $20.32M | $49.23M | $39.77M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.34M | $14.19M | $3.31M | $2.40M | $3.08M | $1.19M |
| Current Assets | $660.78M | $221.34M | $144.70M | $22.65M | $56.64M | $42.89M |
| Total Assets | $683.19M | $240.24M | $148.54M | $24.05M | $57.92M | $44.52M |
| Current Liabilities | $44.99M | $54.31M | $21.83M | $7.33M | $9.73M | $3.04M |
| Long-term Debt | - | - | - | - | - | $134.0K |
| Total Liabilities | $48.84M | $59.08M | $28.66M | $7.39M | $9.74M | $3.18M |
| Stockholders' Equity | $634.34M | $181.16M | $119.88M | $16.65M | $48.19M | $41.34M |
| Retained Earnings | ($728.16M) | ($515.77M) | ($222.81M) | ($116.00M) | ($79.11M) | ($54.39M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($190.92M) | ($110.79M) | ($7.57M) | ($28.69M) | ($18.23M) | ($12.13M) |
| Investing Cash Flow | $60.80M | ($85.06M) | ($30.48M) | ($248.0K) | ($79.0K) | ($586.0K) |
| Financing Cash Flow | $640.36M | $240.53M | $116.41M | $32.0K | $27.77M | $49.94M |
| CapEx | $9.69M | $7.17M | $831.0K | $248.0K | $79.0K | $586.0K |
| Free Cash Flow | ($200.60M) | ($117.97M) | ($8.40M) | ($28.94M) | ($18.30M) | ($12.72M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -3228.8% | -3382.4% | -781.4% | - | - | - |
| EBITDA margin | -3193.3% | -3365.0% | -778.1% | - | - | - |
| Net margin | -3060.0% | -3240.4% | -761.9% | - | - | - |
| Free cash flow margin | -2890.1% | -1304.8% | -59.9% | - | - | - |
| FCF / Net income | 0.94 | 0.40 | 0.08 | 0.78 | 0.74 | 0.71 |
| R&D / Revenue | 2554.2% | 1432.8% | 164.7% | - | - | - |
| SG&A / Revenue | 630.6% | 364.5% | 140.2% | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -31.1% | -121.9% | -71.9% | -153.4% | -42.7% | -40.1% |
| Return on equity | -33.5% | -161.7% | -89.1% | -221.6% | -51.3% | -43.1% |
| Return on invested capital | - | - | - | - | - | -23.4% |
| Liquidity | ||||||
| Current ratio | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 |
| Quick ratio | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 |
| Cash ratio | 14.53 | 2.64 | 4.52 | 2.77 | 5.06 | 13.09 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -583.9x |
| Equity multiplier | 1.08 | 1.33 | 1.24 | 1.44 | 1.20 | 1.08 |
| Liabilities / Assets | 0.07 | 0.25 | 0.19 | 0.31 | 0.17 | 0.07 |
| Efficiency | ||||||
| Asset turnover | 0.01 | 0.04 | 0.09 | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.0x | 3.4x | 1.8x | 1.6x | 0.9x | - |
| P / S | 270.3x | 68.9x | 15.1x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -23.2% | -35.5% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 26.7% | -179.2% | -196.8% | -46.4% | -105.6% | - |
| Net income growth (YoY) | 27.5% | -174.3% | -189.5% | -49.3% | -38.5% | - |
| EPS growth (YoY) | 51.4% | 7.1% | -74.1% | 41.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -70.1% | -1304.5% | 71.0% | -58.1% | -43.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 250.1% | 51.1% | 619.9% | -65.4% | 16.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$6.94M totalSingle Reportable Segment$6.94M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
4.19
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Immunome Inc. against the 5 most active filers in the same SIC group.